Drug intelligence / Profile preview

haloperidol + methylphenidate

Development stage
Unknown
Lead developer
Johnson & Johnson
Modality
Small Molecules
Administration
Oral, Intramuscular, Intravenous, Transdermal
01

Overview

Haloperidol + methylphenidate is a combination of two pharmaceutical drugs, each with distinct mechanisms of action. Haloperidol is a first-generation (typical) antipsychotic that primarily acts as an antagonist at dopamine D2 receptors in the brain, reducing dopaminergic neurotransmission and thereby treating symptoms of psychosis, agitation, and certain behavioral disorders[4][6]. Methylphenidate is a central nervous system stimulant that functions mainly as a norepinephrine–dopamine reuptake inhibitor (NDRI), increasing synaptic concentrations of these neurotransmitters to improve attention and reduce hyperactivity and impulsivity[7][8]. This combination has been studied in children with hyperactivity or aggressive behavior to assess cognitive effects; results suggest small improvements in performance with methylphenidate and low-dose haloperidol[1]. The concurrent use may be considered in complex neuropsychiatric cases but requires careful monitoring due to potential pharmacological interactions.

02

Targets

DRD2 (Dopamine D2 Receptor)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)SIGMAR1 (Sigma non-opioid intracellular receptor 1)

Beyond the preview

Go deeper on haloperidol + methylphenidate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on haloperidol + methylphenidate.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call